These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 32660480)
1. Drug switching in the Netherlands: a cohort study of 20 active substances. Glerum PJ; Maliepaard M; de Valk V; Burger DM; Neef K BMC Health Serv Res; 2020 Jul; 20(1):650. PubMed ID: 32660480 [TBL] [Abstract][Full Text] [Related]
2. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting. Rathe JØ Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397 [TBL] [Abstract][Full Text] [Related]
3. Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands. Glerum PJ; Maliepaard M; de Valk V; Scholl JHG; van Hunsel FPAM; van Puijenbroek EP; Burger DM; Neef K Clin Transl Sci; 2020 May; 13(3):599-607. PubMed ID: 32052597 [TBL] [Abstract][Full Text] [Related]
4. Brand and generic use of inhalation medication and frequency of switching in children and adults: A population-based cohort study. Engelkes M; van Blijderveen JC; Overbeek JA; Kuiper J; Herings RCM; Sturkenboom MCJM; de Jongste JC; Verhamme KMC; Janssens HM J Asthma; 2018 Oct; 55(10):1086-1094. PubMed ID: 29185812 [TBL] [Abstract][Full Text] [Related]
5. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence. Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):944-52. PubMed ID: 27102378 [TBL] [Abstract][Full Text] [Related]
6. Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real-world' retrospective cohort study. Degli Esposti L; Sangiorgi D; Buda S; Degli Esposti E; Scaglione F BMJ Open; 2016 Nov; 6(11):e012003. PubMed ID: 27807083 [TBL] [Abstract][Full Text] [Related]
7. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients. Kwong WJ; Kamat S; Fang C Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Generic Drug Switching: A Regulator's View. Glerum PJ; Neef C; Burger DM; Yu Y; Maliepaard M Clin Pharmacokinet; 2020 Sep; 59(9):1065-1069. PubMed ID: 32557345 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Hess G; Sanders KN; Hill J; Liu LZ Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116 [TBL] [Abstract][Full Text] [Related]
11. A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials. Yu Y; Teerenstra S; Neef C; Burger D; Maliepaard M Br J Clin Pharmacol; 2016 Apr; 81(4):667-78. PubMed ID: 26574160 [TBL] [Abstract][Full Text] [Related]
12. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. Contin M; Alberghini L; Candela C; Benini G; Riva R Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080 [TBL] [Abstract][Full Text] [Related]
13. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of Switch-to-Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real-World Retrospective Cohort Study. Kalaria S; Spence O; Hong K; dosReis S; Gopalakrishnan M Clin Pharmacol Ther; 2021 Aug; 110(2):443-451. PubMed ID: 33811324 [TBL] [Abstract][Full Text] [Related]
15. Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database. Liou WS; Hsieh SC; Chang WY; Wu GH; Huang HS; Lee C Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):752-9. PubMed ID: 23625864 [TBL] [Abstract][Full Text] [Related]
16. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study. Polard E; Nowak E; Happe A; Biraben A; Oger E; Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1161-9. PubMed ID: 26395769 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs. Gagne JJ; Popovic JR; Nguyen M; Sandhu SK; Greene P; Izem R; Jiang W; Wang Z; Zhao Y; Petrone AB; Wagner AK; Dutcher SK Drug Saf; 2018 Dec; 41(12):1313-1323. PubMed ID: 30120741 [TBL] [Abstract][Full Text] [Related]
18. [Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia]. Mainar AS; Artieda RN Gac Sanit; 2010; 24(6):473-82. PubMed ID: 20970220 [TBL] [Abstract][Full Text] [Related]
19. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778 [TBL] [Abstract][Full Text] [Related]
20. Effect of generic-only drug benefits on seniors' medication use and financial burden. Tseng CW; Brook RH; Keeler E; Steers WN; Waitzfelder BE; Mangione CM Am J Manag Care; 2006 Sep; 12(9):525-32. PubMed ID: 16961441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]